ERBB2 and non-small cell lung carcinoma: It has been reported that OSI could induce acquired drug resistance in NSCLC patients40, mainly due to a second mutation of EGFR (such as C797 mutation)41, or activation of by-pass pro-survival signaling pathways such as MET/ERK, HER2, IRE1α or RAS41–44.